SCHEMBL4333175

SCHEMBL4333175

Cn1[nH]c(=O)c(Br)c1C(c1ccccc1)N1CCC(Cc2ccccc2)(C(=O)Oc2ccccc2)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 2/20 0.43
OPRD1 P41143 2/20 0.43
OPRK1 P41145 2/20 0.43
OPRL1 P41146 2/20 0.43
CYP3A4 P08684 7/20 0.41
USP2 O75604 6/20 0.41
CYP1A2 P05177 2/20 0.41
MGLL Q99685 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.37
LMNA P02545 3/20 0.36
CYP2D6 P10635 6/20 0.36
ALDH1A1 P00352 5/20 0.36
CYP2C9 P11712 5/20 0.36
TSHR P16473 1/20 0.36
CYP2C19 P33261 1/20 0.36
HIF1A Q16665 1/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
RECQL P46063 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4325746 0.89 LMNA (0.48) OPRM1OPRD1OPRK1OPRL1L3MBTL1
SCHEMBL4326114 0.89 OPRM1 (0.43) OPRM1OPRD1OPRK1OPRL1L3MBTL1
SCHEMBL4340798 0.78 MGLL (0.41) OPRD1CYP3A4USP2CYP1A2MGLL
SCHEMBL4322729 0.75 KCNA3 (0.40) OPRM1OPRD1OPRK1OPRL1CYP3A4
SCHEMBL4334115 0.75 OPRL1 (0.48) OPRM1OPRD1OPRK1OPRL1LMNA
SCHEMBL4341092 0.74 OPRL1 (0.41) OPRM1OPRD1OPRK1OPRL1CYP3A4
SCHEMBL4322972 0.73 KDM4E (0.39) ALDH1A1TSHRCYP2C19SMN1; SMN2MAPT
SCHEMBL4330985 0.73 SMN1; SMN2 (0.44) OPRM1OPRD1OPRK1OPRL1CYP3A4
SCHEMBL4341190 0.73 OPRL1 (0.43) OPRM1OPRD1OPRK1OPRL1CYP3A4
SCHEMBL4318217 0.71 ADRA1D (0.40) OPRM1OPRD1OPRK1OPRL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090069340-A1 Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders ASTRAZENECA AB (SE) 2009-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069340-A1 Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders GRIN1, GRM1, GRIN3A OPRM1 264/4885OPRD1 178/4885OPRK1 169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.